by Biospring | Apr 26, 2022 | Advanced Therapy, Cell Therapy, CGT, Gene Therapy, Geoffrey Glass, IPSC, Kiniciti, NCardia
In November 2021, we were pleased to announce our investment in Kiniciti, a Cell & Gene Therapy (“CGT”) aggregator. Later in November, Kiniciti announced its first strategic partnership with Ncardia, a leader in developing stem cell-based solutions for...
by Biospring | Apr 26, 2022 | Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Kiniciti
We’re pleased to announce our investment in Kiniciti, a Cell and Gene Therapy (“CGT”) aggregator. We’ve had the pleasure of working with Kiniciti over the past year to identify opportunities in the cell and gene therapy market. Biospring’s...
by Biospring | Apr 26, 2022 | Health Care, Ixlayer, Labs, Precision Health, Telehealth
We are excited to be investors in ixlayer, a company that’s reinventing the health ecosystem by empowering every individual to manage their health testing at home. ixlayer’s technology infrastructure and software is leveraged by large enterprises to enable...
by Biospring | Apr 25, 2022 | Abzena, Biologics, Biotech, CDMO, COVID-19, Drug Development, Drug Discovery, Drug Manufacturing, Pharma, Sven Lee
We shared an overview on Abzena following our investment in July. Over the past few months, Abzena has launched a new facility in San Diego and has made several executive hires. We recently spoke with Sven Lee, Chief Business Officer at Abzena, and he provided us with...
by Biospring | Apr 24, 2022 | Abzena, Biologics, Biotech, CDMO, Drug Development, Pharma
Over the past few months, the COVID-19 pandemic has revealed gaps in the global pharmaceutical supply chain for drugs in clinical trials and for marketed drugs. Drug manufacturing can be a long and complex process requiring specialized expertise. The biopharmaceutical...
